The Medicines and Healthcare products Regulatory Agency (MHRA) has announced a new Community of Practice for Digital Mental Health Technologies, setting out plans for a forum intended to strengthen regulatory understanding, shared learning and practical support for developers.
The announcement, published on the MHRA's official blog, describes a coordinated effort to help innovators navigate regulatory expectations, improve compliance and accelerate safe, effective digital mental health solutions into clinical use. According to the agency, the initiative responds to growing demand for clarity on evidence requirements, post-market responsibilities and the changing regulatory landscape for software-based and AI-enabled mental health tools.
A forum for developers, clinicians and regulators
The community is intended to bring together developers, clinicians, researchers, commissioners and regulatory specialists to build a shared understanding of best practice. The MHRA frames the move as timely: as digital mental health technologies broaden from therapeutic apps to AI-supported assessment tools, the need for consistent, practical guidance has become more urgent.
Stated objectives
- Supporting developers in interpreting regulatory requirements and embedding compliance earlier in product design.
- Identifying challenges that innovators commonly face, particularly small and medium-sized enterprises entering the mental health space.
- Sharing real-world experience from organisations already working through regulatory pathways.
- Strengthening dialogue between industry and regulators so that emerging technologies meet expectations on safety, performance and evidence.
For the wider medtech development community, the agency presents the group as a route to engage directly with the regulator on issues that often decide whether a promising technology reaches patients.
Survey opened to shape priorities
To set the community's initial priorities, the MHRA has opened a survey for digital mental health technology developers and other stakeholders across the medtech ecosystem. The survey explores current regulatory challenges, the areas where clearer guidance is needed and opportunities to improve compliance support.
The agency is encouraging broad participation so that the community reflects real-world needs rather than top-down assumptions, and it invites developers to complete the survey and share the link within their organisations. A strong response, it says, will help the new community deliver practical, meaningful support that accelerates safe, effective innovation for patients.
The announcement sets out the rationale and the consultation route but leaves operational detail open: it does not state how many organisations will take part, how often the community will meet, what form its outputs will take or whether any funding is attached, and it commits to no timetable beyond the initial survey.
For developers, particularly smaller companies, the significance lies in where the regulator says it wants to concentrate attention: earlier compliance, clearer evidence expectations and a more predictable path through regulation. Those remain stated intentions at this stage, and the practical effect will depend on how the community's findings are translated into guidance.